PTK6 and mesothelioma: Notably, PTK6 emerged as a detrimental factor in Adrenocortical carcinoma (ACC), Pancreatic adenocarcinoma (PAAD), Mesothelioma (MESO), Acute Myeloid Leukemia (LAML), Kidney renal clear cell carcinoma (KIRC), and Skin Cutaneous Melanoma (SKCM) (Figure 1B).